ENG

ENG简体中文日本語한국어

  • Roy ZHENG

    Regional Partner / Shanghai

  • Tel +86-21-6061-3653

    Email zhengzekun@zhonglun.com

  • Practices

    Private Equity & Investment Funds, Hong Kong & Overseas Capital Markets, Investment/M&A & Corporate Governance

  • Industries

    Financial Innovation & Fintech, Intelligence Technology & Application, Pharmaceuticals & Life Sciences, Media, Sports & Entertainment

CV

Roy ZHENG

Roy Zheng focuses on private equity, mergers and acquisitions, capital markets, as well as cross-border corporate structuring and governance. His core sector experience spans pharmaceuticals and life sciences, intelligence technology and application, advanced manufacturing, and consumer.

Roy has acted on a range of landmark overseas capital markets deals across the TMT, fintech and consumer sectors, covering IPOs, placings, follow-on offerings, and convertible bonds, etc. He has in particular advised on 20+ capital markets transactions in Hong Kong and the U.S. for biopharmaceutical companies, building deep experience at the leading edge of the market. Per The Legal 500's remarks, Roy Zheng focuses on private equity and is developing a strong overseas capital markets practice, and he is dual-qualified in New York and China, making him an ideal person to advise Chinese companies looking to list overseas.

Roy is a long-standing adviser to prominent multinational corporates, listed companies and investment institutions, supporting them across mergers and acquisitions, joint ventures, cross-border restructuring, corporate governance, and the compliance aspects of day-to-day operations. According to Chambers Great China Guide, a client commented: “Zekun Zheng's client service and general level of service is strong. His level of sophistication and commercial vision is strong.”

Representative Matters

Capital Markets

  • MIXUE Group's HK IPO (China Business Law Journal, 2025 Deals of the Year)

  • CR Beverage's HK IPO (China Business Law Journal, 2024 Deals of the Year)

  • Lufax's NYSE IPO (China Business Law Journal, 2020 Deals of the Year), and dual primary listing by introduction on SEHK

  • Tongcheng Travel's HK IPO

  • Zai Lab's NASDAQ IPO and follow-on offerings, secondary listing on SEHK

  • Everest Medicines' HK IPO and top-up placement

  • CARsgen Therapeutics' HK IPO and top-up placement

  • OcuMension's HK IPO

  • Transcenta's HK IPO

  • Noah Holdings' secondary listing on SEHK

  • Autostreets' HK IPO

  • Qeeka's HK IPO

  • LianBio's NASDAQ IPO (China Business Law Journal, 2022 Deals of the Year)

  • Structure Therapeutics' NASDAQ IPO and follow-on offerings

  • Gracell Biotechnologies' NASDAQ IPO and PIPE placement

  • Adagene's NASDAQ follow-on offerings

  • LC Logistics' placement in Hong Kong

 

Private Equity / Venture Capitals

  • Representation of Geely's Farizon Auto for corporate structuring and equity financing

  • Representation of Synerk for corporate restructuring, equity financing and debt financing, as well as joint collaboration matter

  • Representation of Neukio Biotherapeutics for corporate restructuring

  • Representation of Syntiogen for equity financing

  • Representation of Blackstone for its acquisition of Interplex

  • Representation of Rubicon Founders for its strategic investments in Caidya

  • Representation of Bain Capital Credit for its debt investment in Youran Diary

  • Representation of SoftBank Vision Fund for its multiple investments in intelligence technology and TMT industries

  • Representation of Vertex and Warburg Pincus, respectively, for their investments in Mobike

  • Representation of Qiming and Ares, respectively, for their investments in healthcare and pharmaceutical industries

 

Mergers, Acquisitions and Corporate Matters

  • Representation of General Motors for joint venture matters, corporate restructuring and various compliance matters in business operations

  • Representation of Tongcheng for its merger with E-Dragon, representation of the merged company (Tongcheng-Elong) for strategic financing from Tencent and pre-IPO restructuring, as well as share transfer by Wanda

  • Representation of Tongcheng Travel (formerly, Tongcheng-Elong) for its multiple investments in tourism, real estate and fintech industries

  • Representation of Midea for its strategic acquisition of cross-border medical digital filming assets

  • Representation of PingAn Puhui for its acquisition of internet micro-loan company

  • Representation of Genmab for its various compliance matters in business operations

  • Representation of DreamSmart for its employee shareholding plan and corporate restructuring

  • Representation of Geely's Radar Auto for its corporate structuring

  • Representation of LianBio for its various compliance matters and asset sale

Honors and Awards

Recognized by IFLR1000 as Rising Stars.

Recognized by The Legal 500 Asia Pacific as Next Generation Partners, Rising Stars and recommended as Key Recommended Lawyers.

Related

  • Bar Admissions/Professional Qualifications

    PRC Bar
    New York State Bar

  • Education

    LL.M., The University of Texas at Austin, School of Law
    LL.B., China University of Political Science and Law, School of Law

  • Professional Experience

    Regional partner, non-equity partner, and associate, Zhong Lun Law Firm

  • Languages

    Chinese
    English